Loading...
XNAS
KALA
Market cap30mUSD
Jul 09, Last price  
1.35USD
1D
-2.88%
1Q
-86.70%
IPO
-100.00%
Name

Kala Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:KALA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
50.72%
Rev. gr., 5y
175.60%
Revenues
0k
50,000455,00045,0000006,074,0006,362,00011,240,0003,892,000000
Net income
-27m
L-29.94%
-10,653,000-19,361,000-16,681,999-33,167,000-42,211,000-66,738,000-94,347,000-104,327,000-142,605,000-44,822,000-42,199,000-38,511,000-26,980,000
CFO
-32m
L+8.88%
-10,842,000-15,361,000-15,089,000-27,348,000-34,098,000-54,121,000-92,720,000-90,694,000-108,235,000-78,908,000-27,927,000-29,382,000-31,991,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
URL
https://www.kalarx.com
IPO date
Jul 20, 2017
Employees
34
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT